Importantly, the current data suggest that pre‐treatment features have limited predictive accuracy for BCG immunotherapy sensitivity/resistance and change of cancer cell and immune response status after BCG induction may be more accurate predictors of BCG response, a principle may be applicable to predict anti‐PD‐1/PD‐L1 immunotherapy response. This evidence concerns the gene CD274 and cancer.